Patients who achieved clinical response to mirikizumab at week 12, were re-randomised to receive mirikizumab 200 mg subcutaneously every 4 (n=47) or every 12 weeks (n=46) through week 52. At baseline, 52.7% had previously received a biologic. The main results at week 52 for the respective groups were as follows:
- 46.8% and 37.0% were in clinical remission;
- 80.9% and 76.1% had a clinical response;
- 57.4% and 47.8% had an ES 0/1;
- 61.1% and 38.5% of those in clinical remission at week 12 remained in clinical remission at week 52; and
- 37.9% and 36.4% of those with clinical response, but not in remission, at week 12 achieved clinical remission at week 52.
During the maintenance period, 1 patient discontinued the study due to an adverse event, and similar frequencies of treatment-emergent adverse events and serious adverse events were reported across both treatment groups. This is the first data demonstrating that a p19-directed IL-23 antibody may be an effective maintenance therapy in patients with moderately to severely active ulcerative colitis.
- Reich K, et al. Br J Dermatol. 2019 Feb 7. Doi: 10.1111/bjd.17628. [Epub ahead of print]
- Geert G, et al. ECCO 2019, OP38.
Posted on
Previous Article
« Tofacitinib: Results from the OCTAVE open-label studies Next Article
Efficacy and safety of biosimilars »
« Tofacitinib: Results from the OCTAVE open-label studies Next Article
Efficacy and safety of biosimilars »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
Proactive adalimumab trough measurements
May 9, 2019
p19-Directed IL-23 antibody mirikizumab
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy